Pancreatic ductal adenocarcinoma remains a highly lethal malignancy, with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) representing biologically and anatomically complex ...
Tyvyt plus CRT achieved a 60% pCR rate, outperforming Tyvyt plus chemotherapy (13%) and CRT alone (47.3%). Neoadjuvant Tyvyt plus CRT may become a new standard of care for resectable, locally advanced ...
Impact of surgical timing on outcomes in patients with borderline-resectable and locally advanced pancreatic cancer undergoing neoadjuvant therapy. Evaluation of the impact of GLP-1 receptor agonists ...
Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or ...
SAN DIEGO — Neoadjuvant concurrent chemoradiotherapy significantly improves survival outcomes over adjuvant sequential chemoradiotherapy (ASCRT) in patients with locally advanced esophageal squamous ...
On January 24, 2008, as part of the 2008 Gastrointestinal Cancers Symposium (Orlando, Florida), a 1-day consensus conference was held on resectable and borderline resectable pancreatic adenocarcinoma.
KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results